Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method.
about
Predicting Bevirimat resistance of HIV-1 from genotypeAmino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cellsImproved Bevirimat resistance prediction by combination of structural and sequence-based classifiersA novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness scoreViability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapyStructural and Thermodynamic Basis of Amprenavir/Darunavir and Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50Effect of substrate residues on the P2' preference of retroviral proteinasesA look inside HIV resistance through retroviral protease interaction mapsA consistency-based feature selection method allied with linear SVMs for HIV-1 protease cleavage site predictioniHyd-PseAAC: predicting hydroxyproline and hydroxylysine in proteins by incorporating dipeptide position-specific propensity into pseudo amino acid compositionVirion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 proteaseRole of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivityCoevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease.Bioinformatic approaches for modeling the substrate specificity of HIV-1 protease: an overview.Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients.iCar-PseCp: identify carbonylation sites in proteins by Monte Carlo sampling and incorporating sequence coupled effects into general PseAAC.Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions.Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.iHyd-PseCp: Identify hydroxyproline and hydroxylysine in proteins by incorporating sequence-coupled effects into general PseAAC.Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.pSumo-CD: predicting sumoylation sites in proteins with covariance discriminant algorithm by incorporating sequence-coupled effects into general PseAAC.Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation.Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase.PROSPERous: high-throughput prediction of substrate cleavage sites for 90 proteases with improved accuracy.Support Vector Machines for predicting HIV protease cleavage sites in protein.Computational coevolution of antiviral drug resistance.A Hybrid Deep Learning Model for Predicting Protein Hydroxylation Sites
P2860
Q21284351-9F0A1D77-9224-490E-9979-B99DBAE53D94Q24599011-15BF8687-15AD-4E0E-97DC-CE594FDAC3EEQ24617174-5986CEAE-92C2-49FE-8360-39E104BDF385Q24800445-6DC4A22B-D6BC-4F82-983D-11B7990299E1Q27640250-9B6420CF-DFA6-4AFC-9C6E-D98A6B8ABC80Q27676079-2196073F-D7ED-4117-B6F8-8A78F631CAAFQ28372993-F7B52B3A-B6F8-4CEB-90BC-EAED72A7BC72Q28469157-BD088624-993C-4BD7-A0DB-030B98D21696Q28535597-865C3525-9919-47CF-A311-C11C2FB86AEAQ33755615-96DAEE1B-77C4-490D-BB2D-57B538A8DE0EQ33987368-1D76F602-13D6-4B6A-8F5E-B68058AF3CDFQ34526179-818E1E07-9974-4842-B3D6-2B8980843001Q34717635-3780168D-AEE6-467D-914C-003552300975Q34990918-7869EAE8-2E68-47F1-80DA-9EF7143806ECQ36874356-A261140A-2E22-464A-8210-DB1133217DA1Q36951677-4B181BBA-76F4-46DC-8C10-5BA230791FF0Q37376337-6528B776-981D-482E-B4FF-5F8A3E3CAA19Q37452008-2F1654A6-6569-4E2E-AA4F-CDE9D6C91A17Q37463212-F1764654-529D-43D4-BDFA-2A4281000DC5Q37536872-98B88167-7DED-42CA-B5E0-1CCCF0D60FCCQ37583444-1A403931-3B16-4E21-9162-3DC4C311F72FQ37596952-67325DB0-F218-4631-9C43-579C7A070622Q39646826-2972983E-88C1-4B6A-A45D-48A65CF4D126Q40005589-BD8B64BA-6767-4ECE-96A8-CFD555C5B2B6Q42545682-D70703E6-628D-486B-8DFF-55E0E31EB4D5Q47605405-CDE5B79B-D2D1-4603-B8D8-D0C76ACA5822Q52043614-365B04BE-ECD5-4DF7-9526-ECB4FB0885A5Q52232508-49E410D6-0A67-4837-8964-8E7D18F73B86Q58722840-56F33D46-3DD1-4924-B6B3-4183B7CFB9AA
P2860
Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Predicting human immunodeficie ...... discriminant function method.
@ast
Predicting human immunodeficie ...... discriminant function method.
@en
Predicting human immunodeficie ...... discriminant function method.
@nl
type
label
Predicting human immunodeficie ...... discriminant function method.
@ast
Predicting human immunodeficie ...... discriminant function method.
@en
Predicting human immunodeficie ...... discriminant function method.
@nl
prefLabel
Predicting human immunodeficie ...... discriminant function method.
@ast
Predicting human immunodeficie ...... discriminant function method.
@en
Predicting human immunodeficie ...... discriminant function method.
@nl
P2093
P2860
P1433
P1476
Predicting human immunodeficie ...... discriminant function method.
@en
P2093
Heinrikson RL
Reardon IM
Tomasselli AG
P2860
P356
10.1002/(SICI)1097-0134(199601)24:1<51::AID-PROT4>3.0.CO;2-R
P407
P577
1996-01-01T00:00:00Z